Lechleiter’s reign at Lilly

  • Comments
  • Print

Tomorrow, John Lechleiter takes over from
Sidney Taurel as CEO of Eli Lilly and Co.

A chemist who came up through Lillyâ??s labs, marketing and finally, as president and chief operating officer, Lechleiter
major pressure.

Lilly stock has trended sideways for more than three years as investors impatiently look for news that the company can replace
its top-selling Zyprexa and other major drugs as their patents expire.

With state government as a major employer as well as lots of small- and medium-sized businesses across a number of sectors,
Indianapolis enjoys economic stability many cities can only dream of. But Lilly is still critical to the regionâ??s prosperity.

How do you feel about Lillyâ??s future under Lechleiter?

Please enable JavaScript to view this content.

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our updated comment policy that will govern how comments are moderated.